公开(公告)号：US20190185462A1

公开(公告)日：2019-06-20

申请号：US16309390

申请日：2017-06-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： Abbas Walji ,  Richard Berger ,  Craig A. Stump ,  Kelly Ann S. Schlegel ,  James J. Mulhearn ,  Thomas J. Greshock ,  Deping Wang ,  Mark E. Fraley ,  Kristen G. Jones

IPC: C07D413/10 ,  C07D413/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D491/052 ,  C07D498/04 ,  C07D513/04 ,  C07D271/06 ,  C07D471/14 ,  A61P25/28 ,  A61P25/18 ,  A61P29/00 ,  A61P11/06 ,  A61P3/10 ,  A61P35/00 ,  A61P37/02

CPC classification number: C07D413/10 ,  A61K45/06 ,  A61P3/10 ,  A61P9/00 ,  A61P11/06 ,  A61P25/18 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  C07D271/06 ,  C07D271/113 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/048 ,  C07D491/052 ,  C07D498/04 ,  C07D513/04 ,  C07F7/0807

Abstract: The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.